Treats generalized anxiety disorder. ANDA 78561, held by Actavis Elizabeth. Alprazolam.
As of Nov 15, 2026, ANDA 78561 (Alprazolam), held by Actavis Elizabeth, was first approved by FDA on Mar 16, 2010, with 6 approved supplements and 0 published complete response letters.
Alprazolam orally disintegrating tablets are a benzodiazepine indicated for: The treatment of generalized anxiety disorder. The efficacy of alprazolam was demonstrated in 5 short-term, placebo-controlled trials.. The treatment of panic disorder, with or without agoraphobia. The efficacy of alprazolam in the treatment of panic disorder was established in 2 short-term, placebo-controlled trials. 1.1 Generalized Anxiety Disorder Alprazolam orally disintegrating tablets, USP are indicated for the treatment of generalized anxiety disorder. The efficacy of alprazolam in the treatment of generalized anxiety disorder was demonstrated in 5 short-term, placebo-controlled trials. 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 16, 2010 | Original application | Approved | None posted |
| Alprazolam0.25MG · tablet, orally disintegrating;oral | Alprazolam | Rx |
| Alprazolam0.5MG · tablet, orally disintegrating;oral | Alprazolam | Rx |
| Alprazolam1MG · tablet, orally disintegrating;oral | Alprazolam | Rx |
| Alprazolam2MG · tablet, orally disintegrating;oral | Alprazolam | Rx |
| Jan 17, 2023 | Supplement 24Labeling · Standard review | Approved | None posted |
| Jan 5, 2023 | Supplement 23Labeling · Standard review | Approved | None posted |
| Feb 5, 2021 | Supplement 22Labeling · Standard review | Approved | None posted |
| Dec 16, 2016 | Supplement 15Labeling · Standard review | Approved | None posted |
| Dec 16, 2016 | Supplement 14Labeling · Standard review | Approved | None posted |
| Nov 18, 2016 | Supplement 13Labeling · Standard review | Approved | None posted |
| Mar 16, 2010 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters